Mel Gibson on covid: what the evidence says · JRE #2254

What the evidence says 01 / RECORD

Remdesivir's FDA prescribing information lists acute kidney injury and reduced eGFR/creatinine clearance among reported adverse reactions and laboratory abnormalities in clinical trials, occurring in a small minority of patients (acute kidney injury was cited as a reason for treatment discontinuation in 3 of roughly 200 subjects in one trial arm), not as a common or defining effect of the drug. A 2025 systematic review and meta-analysis in BMC Infectious Diseases, covering one randomized controlled trial and 14 cohort studies, found that among COVID-19 patients with severe renal impairment, remdesivir use was associated with a significantly lower incidence of kidney injury compared with not receiving the drug (risk ratio 0.51, 95% CI 0.27 to 0.97), and no significant increase in mortality. Kidney injury incidence was higher in patients who already had severe renal impairment regardless of remdesivir exposure, not specifically attributable to the drug. The FDA label notes that remdesivir's pharmacokinetics have not been fully evaluated in patients with renal impairment and recommends renal monitoring during treatment, reflecting a precaution rather than an established causal link to kidney failure. Current evidence therefore does not support the claim that remdesivir causes kidney failure; it can be associated with kidney-related lab abnormalities and acute kidney injury in a minority of patients, but cohort and meta-analytic data do not show it as a leading or frequent cause of renal failure, and in high-risk renal patients it has not been shown to worsen kidney outcomes compared with non-use.